Találati lista | Tudóstér

001-es BibID:	BIBFORM028432
Első szerző:	Meggyesi Nóra
Cím:	NKX2-3 and IRGM variants are associated with disease susceptibility to IBD in Eastern European patients / Nora Meggyesi, Lajos S. Kiss, Magdalena Koszarska, Martin Bortlik, Dana Duricova, Laszlo Lakatos, Tamas Molnar, Martin Leniček, Libor Vítek, Istvan Altorjay, Maria Papp, Zsolt Tulassay, Pal Miheller, Janos Papp, Attila Tordai, Hajnalka Andrikovics, Milan Lukas, Péter Lakatos
Dátum:	2010
ISSN:	1007-9327
Megjegyzések:	To investigate variants of immunity-related GTPase family M (IRGM) and NKX2-3 genes and genotype-phenotype in Eastern European patients with inflammatory bowel disease (IBD). METHODS: We analyzed 1707 Hungarian and Czech subjects with Crohn's disease (CD) (n = 810, age: 37.1 ± 12.6 years, duration: 10.7 ± 8.4 years) and ulcerative colitis (UC) (n = 428, age: 43.7 ± 15.0 years, duration: 12.6 ± 9.9 years), as well as 469 healthy controls. IRGM rs13361189, NKX2-3 rs10883365 and ECM1 rs13294 polymorphisms were tested by LightCycler allele discrimination. Detailed clinical phenotypes were determined by reviewing the medical charts. RESULTS: NKX2-3 rs10883365 variant allele was associated with increased risk for CD (P = 0.009, OR = 1.24, 95% CI = 1.06-1.48) and UC (P = 0.001, OR = 1.36, 95% CI = 1.13-1.63), whereas variant IRGM allele increased risk for CD (P = 0.029, OR = 1.36, 95% CI = 1.03-1.79). In contrast, ECM1 rs13294 was not associated with either CD or UC. In CD, the variant IRGM allele was associated with a colon-only location (P = 0.02, OR = 1.62, 95% CI = 1.07-2.44), whereas in UC, the ECM1 variant was associated with cutaneous manifestations (P = 0.002, OR = 3.36, 95% CI = 1.48-7.63). Variant alleles did not predict resistance to steroids or azathioprine, efficacy of infliximab, or need for surgery. CONCLUSION: NKX2-3 and IRGM are susceptibility loci for IBD in Eastern European patients. Further studies are needed to confirm the reported phenotype-genotype associations.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk egyetemen (Magyarországon) készült közlemény
Megjelenés:	World Journal of Gastroenterology. - 16 : 41 (2010), p. 5233-5240. -
További szerzők:	Kiss Lajos Sándor Koszarska, Magdalena Bortlik, Martin Duricova, Dana Lakatos László (Veszprém) Molnár Tamás (orvos Szeged) Leniček, Martin Vítek, Libor Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) Papp Mária (1975-) (belgyógyász, gasztroenterológus) Tulassay Zsolt (1944-) (belgyógyász, gasztroenterológus) Miheller Pál Papp János (Budapest) Tordai Attila Andrikovics Hajnalka Lukas, Milan Lakatos Péter (Semmelweis Egyetem)
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM066565
Első szerző:	Regueiro, Miguel
Cím:	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection / Miguel Regueiro, Brian G. Feagan, Bin Zou, Jewel Johanns, Marion A. Blank, Marc Chevrier, Scott Plevy, John Popp, Freddy J. Cornillie, Milan Lukas, Silvio Danese, Paolo Gionchetti, Stephen B. Hanauer, Walter Reinisch, William J. Sandborn, Dario Sorrentino, Paul Rutgeerts, PREVENT Study Group
Dátum:	2016
ISSN:	0016-5085
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:	Gastroenterology 150 : 7 (2016), p. 1568-1578. -
További szerzők:	Feagan, Brian Zou, Bin Johanns, Jewel Blank, Marion Chevrier, Marc Plevy, Scott Popp, John Cornillie, Freddy J. Lukas, Milan Danese, Silvio Gionchetti, Paolo Hanauer, Stephen B. Reinisch, Walter Sandborn, William J. Sorrentino, Dario Rutgeerts, Paul Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) PREVENT Study Group
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM036070
Első szerző:	Tromm, Andreas
Cím:	Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease / Andreas Tromm, Ivan Bunganič, Eva Tomsová, Zsolt Tulassay, Milan Lukáš, Jan Kykal, Marian Bátovský, Bohumil Fixa, Libor Gabalec, Rifaat Safadi, Heinz-Jochen Kramm, István Altorjay, Hanns Löhr, Ioannis Koutroubakis, Simon Bar-Meir, Davor Štimac, Elke Schäffeler, Christoph Glasmacher, Karin Dilger, Ralf Mohrbacher, Roland Greinwald, and the International Budenofalk Study Group
Dátum:	2011
ISSN:	0016-5085
Megjegyzések:	Comparative data on budesonide vs mesalamine for the treatment of mild-to-moderately active Crohn's disease (CD) are sparse. We assessed the efficacy and safety of each therapy in patients with mildly to moderately active CD. METHODS: We performed a randomized, double-blind, double-dummy, 8-week, multicenter study in which 309 patients with mildly to moderately active CD received pH-modified-release oral budesonide (9 mg/day once daily or 3 mg/day 3 times daily) or Eudragit-L-coated oral mesalamine (4.5 g/day). RESULTS: The primary efficacy variable, clinical remission (defined as Crohn's Disease Activity Index 150), at the final visit occurred in 69.5% (107 of 154) of patients given budesonide vs 62.1% (95 of 153) of patients given mesalamine (difference, 7.4%; 95% repeated confidence interval, -4.6% to 18.0%; P = .001 for noninferiority). Clinical remission rates did not differ significantly between the 2 budesonide groups. Treatment response, defined as Crohn's Disease Activity Index of 150 or less and/or a decrease of 70 or more (70) or 100 or more (100) points from baseline to final visit, did not differ significantly between patients given budesonide vs mesalamine (70, P = .11; 100, P = .15), or between the 2 budesonide groups (70, P = .38; 100, P = .78). No other efficacy end points differed significantly between groups. Discontinuation because of adverse events occurred in 3% and 5% of budesonide- and mesalamine-treated patients, respectively. There were no clinically relevant differences in adverse events between the 2 budesonide groups. CONCLUSIONS: Budesonide (9 mg/day) was numerically, but not statistically, more effective than Eudragit-L-coated mesalamine (4.5 g/day) in patients with mildly to moderately active CD. Budesonide (9 mg/day), administered once daily, was as effective as the standard (3 times daily) regimen.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban külföldön készült közlemény
Megjelenés:	Gastroenterology 140 : 2 (2011), p. 425-434. -
További szerzők:	Bunganič, Ivan Tomsová, Eva Tulassay Zsolt (1944-) (belgyógyász, gasztroenterológus) Lukas, Milan Kykal, Jan Bátovský, Marian Fixa, Bohumil Gabalec, Libor Safadi, Rifaat Kramm, Heinz-Jochen Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) Löhr, Hanns Koutroubakis, Ioannis Bar-Meir, Simon Štimac, Davor Schäffeler, Elke Glasmacher, Christoph Dilger, Karin Mohrbacher, Ralf Greinwald, Roland International Budenofalk Study Group
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon: